doi: 10.5732/cjc.012.10287

Molecular mechanisms of tumor resistance to PI3K-mTOR-targeted therapy

Jing Tan, Qiang Yu

Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, A*STAR (Agency for Science, Technology and Research), Biopolis, Singapore 138672, Singapore

[Abstract] Deregulation of the phosphatidylinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) signaling pathway occurs frequently in a wide range of human cancers and is a major driving force in tumorigenesis. Thus, small molecules targeting this pathway are under active development as anticancer therapeutics. Although small-molecule inhibitors of the PI3K-mTOR pathway have shown promising clinical efficacy against human cancers, the emergence of drug resistance may limit their success in the clinic. To date, several resistance mechanisms, including both PI3K-dependent and -independent mechanisms, have been described. Here, we summarize the current understanding of resistance mechanisms to PI3K-mTOR inhibitors and discuss potential strategies for overcoming resistance for potential clinical application.

Chinese Journal of Cancer 2013, Volume: 32, Issue 7, Page: 376-379

[ PDF Full-text ]
[ Html full-text ](PubMed Central)
[ PubMed ]
[Google Scholar]

Cite this article

Jing Tan, Qiang Yu. Molecular mechanisms of tumor resistance to PI3K-mTOR-targeted therapy . Chin J Cancer. 2013, 32(7):376-379. doi:10.5732/cjc.012.10287


Export citations

EndNote